Article Text

Download PDFPDF
Unilateral macular oedema in Zermatt and Stargardt macular dystrophies
  1. H Abouzeid1,
  2. T J Wolfensberger1,
  3. D F Schorderet2,3,
  4. F L Munier1
  1. 1
    Jules-Gonin Eye Hospital, Lausanne, Switzerland
  2. 2
    Institut de Recherche en Ophtalmologie, Sion, Switzerland
  3. 3
    Ecole polytechnique fédérale de Lausanne, Lausanne, Switzerland
  1. Correspondence to Professor F L Munier, Jules-Gonin Eye Hospital, 15 avenue de France, CH-1004 Lausanne, Switzerland; francis.munier{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Zermatt macular dystrophy is a dominantly inherited pattern dystrophy caused by the R172W mutation of the RDS/peripherin gene and named after the Zermatt area of Switzerland.1 It shows small and round macular drusen early in life which are characterised by a very bright and early hyperfluorescent pattern suggestive of basal laminar drusen.1 Geographical atrophy occurs during the end stage of the disease. Stargardt dystrophy is a common recessively inherited disease caused by mutations in the ABCA4 gene2 with yellow-white, irregularly shaped flecks at the level of the retinal pigment epithelium (RPE) and atrophy occurring later as the disease progresses.3

Case reports

Case 1

A 45-year-old woman with a 10-year history of a retinal dystrophy resulting from an R172W mutation in the RDS/peripherin gene (Zermatt dystrophy) presented with a 6-week history of visual loss in the left eye. On presentation, the Snellen best-corrected visual acuity (BCVA) was 0.3 in both eyes. Eight weeks before the described symptoms, visual acuity was recorded as 0.3 in the right and 0.8 in the left eye, and a normal foveal depression was observed on optical coherence tomography (OCT) (right eye: 128 μm; left eye: 148 μm) (Zeiss-Meditec, Dublin, California). Complete ophthalmic examination, autofluorescence, fluorescein angiography and OCT were performed (fig 1).

Figure 1

Case 1: 45-year-old woman with Zermatt dystrophy. Left eye. (A) Fundus autofluorescence, HRA. (B) Fluorescein angiography. (C) Optical coherence tomography (OCT) 3. Before treatment. (D) OCT 3. Five weeks after treatment.

Case 2

A 43-year-old man, who was diagnosed 2 months previously with Stargardt …

View Full Text